B-cell Maturation Antigen

Where the papers sit

12 papers from the last 6 months study B-cell Maturation Antigen directly · updated from PubMed 1 Nov 2026

• BCMA-Directed Treatment in Myeloma

  BCMA-directed treatment is broadening from CAR T cells to bispecific antibodies and antibody-drug conjugates in relapsed/refractory myeloma. Ciltacabtagene autoleucel and anito-cel studies emphasize activity, while teclistamab and belantamab analyses add real-world safety and pharmacokinetic evidence. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome recur as key risks, including in frail patients. Epitope engagement, BCMA mutations, soluble BCMA, and serum M-protein are emerging as determinants of response and treatment monitoring.

  5 papers · 41.7%

• Cellular Immunotherapy for Myeloma

  BCMA cellular immunotherapy is expanding beyond conventional autologous CAR-T toward triple-knockout allogeneic CAR T cells and CAR-NK cells. Early studies prioritize feasibility, cytotoxicity, and durable responses in heavily treated disease. Durable drug-free remission after BCMA CAR T-cell therapy also broadens interest beyond myeloma to antibody-mediated disorders. CTLA4 and LAG3 polymorphisms may help explain differences in response, but clinical evidence remains early.

  5 papers · 41.7%

• BCMA-Targeted Outcomes

  BCMA-targeted therapies are being evaluated across relapsed or refractory multiple myeloma and AL amyloidosis, with bispecific antibodies among the central approaches. Progression-free survival and median time to next treatment remain the principal outcome measures. The evidence is largely descriptive, drawing on the French EMMY real-world cohort and pooled analyses rather than direct comparative trials. The field is moving toward broader disease application, while comparative effectiveness and long-term safety remain unresolved.

  2 papers · 16.7%